Efficacy of the Vaccine Candidate Based on the P0 Peptide against <i>Dermacentor nitens</i> and <i>Ixodes ricinus</i> Ticks
Alina Rodríguez-Mallon,
Pedro E. Encinosa Guzmán,
Yamil Bello,
Ana Domingos,
Sandra Antunes,
Petr Kopacek,
Ana Sofia Santos,
Rita Velez,
Jan Perner,
Frank L. Ledesma Bravo,
Helena Frantova,
Jan Erhart,
Rafmary Rodríguez,
Alier Fuentes,
David Diago,
Marisdania Joglar,
Luis Méndez,
Mario Pablo Estrada
Affiliations
Alina Rodríguez-Mallon
Center for Genetic Engineering and Biotechnology (CIGB), 31st Avenue and 190, Havana 10600, Cuba
Pedro E. Encinosa Guzmán
Center for Genetic Engineering and Biotechnology (CIGB), 31st Avenue and 190, Havana 10600, Cuba
Yamil Bello
Center for Genetic Engineering and Biotechnology (CIGB), 31st Avenue and 190, Havana 10600, Cuba
Ana Domingos
Global Health and Tropical Medicine, GHTM, Associate Laboratory in Translation and Innovation towards Global Health, LA-REAL, Instituto de Higiene e Medicina Tropical, IHMT, Universidade Nova de Lisboa, UNL, Rua da Junqueira 100, 1349-008 Lisboa, Portugal
Sandra Antunes
Global Health and Tropical Medicine, GHTM, Associate Laboratory in Translation and Innovation towards Global Health, LA-REAL, Instituto de Higiene e Medicina Tropical, IHMT, Universidade Nova de Lisboa, UNL, Rua da Junqueira 100, 1349-008 Lisboa, Portugal
Petr Kopacek
Institute of Parasitology, Biology Centre, Czech Academy of Sciences, 37005 České Budějovice, Czech Republic
Ana Sofia Santos
Centro de Estudos de Vetores e Doenças Infeciosas Dr. Francisco Cambournac, Instituto Nacional de Saúde Doutor Ricardo Jorge (CEVDI-INSA), 2965-575 Águas de Moura, Portugal
Rita Velez
Centro de Estudos de Vetores e Doenças Infeciosas Dr. Francisco Cambournac, Instituto Nacional de Saúde Doutor Ricardo Jorge (CEVDI-INSA), 2965-575 Águas de Moura, Portugal
Jan Perner
Institute of Parasitology, Biology Centre, Czech Academy of Sciences, 37005 České Budějovice, Czech Republic
Frank L. Ledesma Bravo
Center for Genetic Engineering and Biotechnology (CIGB), 31st Avenue and 190, Havana 10600, Cuba
Helena Frantova
Institute of Parasitology, Biology Centre, Czech Academy of Sciences, 37005 České Budějovice, Czech Republic
Jan Erhart
Institute of Parasitology, Biology Centre, Czech Academy of Sciences, 37005 České Budějovice, Czech Republic
Rafmary Rodríguez
National Laboratory of Parasitology, Avenue San Antonio-Rincón, Km 1 1/2, Artemisa 32500, Cuba
Alier Fuentes
National Laboratory of Parasitology, Avenue San Antonio-Rincón, Km 1 1/2, Artemisa 32500, Cuba
David Diago
Center for Genetic Engineering and Biotechnology (CIGB), 31st Avenue and 190, Havana 10600, Cuba
Marisdania Joglar
Center for Genetic Engineering and Biotechnology (CIGB), 31st Avenue and 190, Havana 10600, Cuba
Luis Méndez
National Laboratory of Parasitology, Avenue San Antonio-Rincón, Km 1 1/2, Artemisa 32500, Cuba
Mario Pablo Estrada
Center for Genetic Engineering and Biotechnology (CIGB), 31st Avenue and 190, Havana 10600, Cuba
The control of ticks through vaccination offers a sustainable alternative to the use of chemicals that cause contamination and the selection of resistant tick strains. However, only a limited number of anti-tick vaccines have reached commercial realization. In this sense, an antigen effective against different tick species is a desirable target for developing such vaccines. A peptide derived from the tick P0 protein (pP0) conjugated to a carrier protein has been demonstrated to be effective against the Rhipicephalus microplus, Rhipicephalus sanguineus, and Amblyomma mixtum tick species. The aim of this work was to assess the efficacy of this peptide when conjugated to the Bm86 protein against Dermacentor nitens and Ixodes ricinus ticks. An RNAi experiment using P0 dsRNA from I. ricinus showed a dramatic reduction in the feeding of injected female ticks on guinea pigs. In the follow-up vaccination experiments, rabbits were immunized with the pP0-Bm86 conjugate and challenged simultaneously with larvae, nymphs, and the adults of I. ricinus ticks. In the same way, horses were immunized with the pP0-Bm86 conjugate and challenged with D. nitens larva. The pP0-Bm86 conjugate showed efficacies of 63% and 55% against I. ricinus and D. nitens ticks, respectively. These results, combined with previous reports of efficacy for this conjugate, show the promising potential for its development as a broad-spectrum anti-tick vaccine.